ASX:PNV - Polynovo Stock Price, News & Analysis

Today's Range N/A
50-Day Range
MA: A$1.65
52-Week Range N/A
Volume3.42 million shs
Average VolumeN/A
Market Capitalization$1.16 billion
P/E RatioN/A
Dividend YieldN/A
Polynovo Limited, a medical device company, designs, develops, and manufactures dermal regeneration solutions in Australia. The company focuses on the development and commercialization of medical devices using its NovoSorb technology in the treatment of burns, surgical wounds, and negative pressure wound therapy. It offers BTM (biodegradable temporising matrix), a wound dressing intended for treatment of full-thickness wounds and burns. In addition, Polynovo Limited licensed its NovoSorb to Smith & Nephew for orthopaedic applications. The company was formerly known as Calzada Limited and changed its name to Polynovo Limited in November 2014. Polynovo Limited is based in Port Melbourne, Australia.

Industry, Sector and Symbol

Industry Biotechnology
Phone61 3 8681 4050



Sales & Book Value

Annual Sales$8.66 million
Book ValueA$0.04 per share



Market Cap$1.16 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive PNV News and Ratings via Email

Sign-up to receive the latest news and ratings for PNV and its competitors with MarketBeat's FREE daily newsletter.

Polynovo (ASX:PNV) Frequently Asked Questions

What is Polynovo's stock symbol?

Polynovo trades on the ASX under the ticker symbol "PNV."

Has Polynovo been receiving favorable news coverage?

Media headlines about PNV stock have trended positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Polynovo earned a news sentiment score of 2.5 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the immediate future. View News Stories for Polynovo.

Who are some of Polynovo's key competitors?

What other stocks do shareholders of Polynovo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Polynovo investors own include Vanguard FTSE Pacific ETF (VPL) and Acasti Pharma (ACST).

Who are Polynovo's key executives?

Polynovo's management team includes the folowing people:
  • Mr. Paul Brennan, Chief Exec. Officer
  • Mr. Greg Lewis M.A.I.C.D., M.B.A., Chief Operating Officer
  • Mr. Jan-Marcel Gielen, CFO & Company Sec.
  • Dr. Tim Moore, Principal Scientist
  • Mr. David Smith, Manufacturing Mang.

How big of a company is Polynovo?

Polynovo has a market capitalization of $0.00 and generates $8.66 million in revenue each year. Polynovo employs 41 workers across the globe.View Additional Information About Polynovo.

What is Polynovo's official website?

The official website for Polynovo is

How can I contact Polynovo?

The company can be reached via phone at 61 3 8681 4050.

MarketBeat Community Rating for Polynovo (ASX PNV)

Community Ranking:  2.5 out of 5 (star star)
Outperform Votes:  12 (Thanks for Voting!)
Underperform Votes:  12 (Thanks for Voting!)
Total Votes:  24
MarketBeat's community ratings are surveys of what our community members think about Polynovo and other stocks. Vote "Outperform" if you believe PNV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PNV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/23/2019 by Staff

Featured Article: Lock-Up Period Expiration

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel